StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.43−0.40 (-10.44%)

Close on Nov 17, 2026Market cap $66.34MP/E –Yield –

Kala Bio total assets

Total assets on the balance sheet at the end of each period.

Kala Bio's total assets was $10.58M at Jun 30, 2026. For fiscal 2025 it was $9.49M, down 82.9% from the year before. The highest annual figure on record is $221.61M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.49M-82.9%
FY2024Dec 31, 2024$55.48M-0.8%
FY2023Dec 31, 2023$55.95M-35.6%
FY2022Dec 31, 2022$86.82M-37.7%
FY2021Dec 31, 2021$139.43M-37.1%
FY2020Dec 31, 2020$221.61M+43.6%
FY2019Dec 31, 2019$154.32M-30.2%
FY2018Dec 31, 2018$220.97M+89.6%
FY2017Dec 31, 2017$116.55M+151.6%
FY2016Dec 31, 2016$46.33M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$10.58M-70.6%
Q1 FY2026Mar 31, 2026$12.32M-74.5%
Q4 FY2025Dec 31, 2025$9.49M-82.9%
Q3 FY2025Sep 30, 2025$25.02M-53.7%
Q2 FY2025Jun 30, 2025$36.05M-41.5%
Q1 FY2025Mar 31, 2025$48.25M-9.0%
Q4 FY2024Dec 31, 2024$55.48M-0.8%
Q3 FY2024Sep 30, 2024$54.08M-11.5%
Q2 FY2024Jun 30, 2024$61.61M-7.4%
Q1 FY2024Mar 31, 2024$53.03M-26.6%
Q4 FY2023Dec 31, 2023$55.95M-35.6%
Q3 FY2023Sep 30, 2023$61.12M-28.7%
Q2 FY2023Jun 30, 2023$66.50M-21.7%
Q1 FY2023Mar 31, 2023$72.23M-35.3%
Q4 FY2022Dec 31, 2022$86.82M-37.7%
Q3 FY2022Sep 30, 2022$85.70M-55.8%
Q2 FY2022Jun 30, 2022$84.98M-60.6%
Q1 FY2022Mar 31, 2022$111.57M-51.5%
Q4 FY2021Dec 31, 2021$139.43M-37.1%
Q3 FY2021Sep 30, 2021$193.81M-13.9%
Q2 FY2021Jun 30, 2021$215.46M-12.2%
Q1 FY2021Mar 31, 2021$229.83M-11.1%
Q4 FY2020Dec 31, 2020$221.61M+43.6%
Q3 FY2020Sep 30, 2020$225.10M+39.8%
Q2 FY2020Jun 30, 2020$245.51M+37.3%
Q1 FY2020Mar 31, 2020$258.53M+31.2%
Q4 FY2019Dec 31, 2019$154.32M-30.2%
Q3 FY2019Sep 30, 2019$161.01M+91.5%
Q2 FY2019Jun 30, 2019$178.82M+87.1%
Q1 FY2019Mar 31, 2019$197.02M+87.7%
Q4 FY2018Dec 31, 2018$220.97M+89.6%
Q3 FY2018Sep 30, 2018$84.08M-32.0%
Q2 FY2018Jun 30, 2018$95.59M+234.3%
Q1 FY2018Mar 31, 2018$104.99M+126.6%
Q4 FY2017Dec 31, 2017$116.55M–
Q3 FY2017Sep 30, 2017$123.69M–
Q2 FY2017Jun 30, 2017$28.59M–
Q4 FY2016Dec 31, 2016$46.33M–

More Kala Bio figures

See a number that looks wrong?